Lynparza is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer
Calquence shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukaemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib
Imfinzi five-year data represent longest-ever survival reported in a Phase III immunotherapy trial in unresectable Stage III lung cancer
/Public Release. View in full here.
